Churchill Pharmaceuticals

What Churchill Pharmaceuticals does

Churchill Pharmaceuticals is a privately held U.S.-registered entity (King, United States; 1-10 employees) that operates as a dedicated clinical-trial brand for the PACIFICA Phase 3 program of pacritinib. The website churchillpharma.com serves as a health-care-professional portal describing trial design, eligibility criteria, enrollment status, and contact channels ([email protected]), with the site footer attributing operation to Swedish Orphan Biovitrum AB (publ) (Sobi) and privacy/terms links redirecting to sobi.com.

The core product addressed through this portal is pacritinib, commercially marketed as VONJO™, a Janus kinase 2 (JAK2) inhibitor that received U.S. Food and Drug Administration approval on February 28, 2022 for adults with myelofibrosis and a platelet count below 50 x 10^9/L (severe thrombocytopenia). The PACIFICA trial is a randomized, controlled Phase 3 study comparing pacritinib against a Physician's Choice arm (limited to single-agent corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib per country), enrolling adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. Primary endpoints are ≥35% spleen volume reduction (SVR35) and ≥50% reduction in Total Symptom Score (TSS50) at Week 24, with Patient Global Impression of Change (PGIC) and overall survival as secondary endpoints.

Churchill Pharmaceuticals does not, on the disclosed evidence, sell a product, collect revenue, or maintain a salesforce; its commercial mechanics sit with Sobi, which is the named developer and commercial sponsor of pacritinib. Trial-site distribution spans approximately 24 countries (North America, Western and Eastern Europe, Asia-Pacific, Middle East, Latin America), with U.S. enrollment closed in March 2022 following FDA approval and enrollment in the Russian Federation and Ukraine closed (geographic details:). Pricing for VONJO™ is not disclosed on the portal, and no revenue model, headcount scale, or partnership-economics are disclosed for the Churchill entity itself.

Name

Churchill Pharmaceuticals

Legal name

Swedish Orphan Biovitrum AB (publ)

Website

https://churchillpharma.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Churchill Pharmaceuticals is a privately held U.S. clinical-trial brand operating the PACIFICA Phase 3 trial of pacritinib (VONJO™), a JAK2 inhibitor, in myelofibrosis patients with severe thrombocytopenia, on behalf of developer Sobi.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Oncology / Hematology)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Myelofibrosis treatment
• JAK2 inhibitor drugs
• Specialty pharmaceuticals
• Clinical research oncology
• Rare disease therapeutics

Headquarters

HQ city

King

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Marketing channels1 record

Core offering

Churchill Pharmaceuticals operates a clinical trial information portal for the PACIFICA Phase 3 study evaluating pacritinib (commercially marketed as VONJO™), a Janus kinase 2 (JAK2) inhibitor, in patients with myelofibrosis and severe thrombocytopenia (platelet counts below 50 x 10⁹/L). The portal educates healthcare professionals on study design, eligibility criteria, and enrollment, while the underlying drug has received FDA approval (February 28, 2022) for the same indication.

Product overview

Churchill Pharmaceuticals offers a focused clinical development and commercialization portfolio centered on pacritinib. The company's primary product is VONJO™ (pacritinib), an FDA-approved JAK2 inhibitor for treating myelofibrosis patients with severe thrombocytopenia. The PACIFICA clinical trial portal serves as an educational resource for healthcare professionals about the ongoing Phase 3 clinical study of pacritinib versus Physician's Choice therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• VONJO™ (pacritinib) FDA-approved JAK2 inhibitor (pacritinib) for the treatment of adults with myelofibrosis and severe thrombocytopenia (platelet count <50 x 10⁹/L), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It is the only JAK2 inhibitor specifically indicated for this underserved patient population.
• PACIFICA Clinical Trial Randomized, controlled Phase 3 clinical study comparing pacritinib versus Physician's Choice therapy (corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib) in patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet counts <50,000/μL). Primary endpoints include ≥35% spleen volume reduction (SVR) and ≥50% reduction in Total Symptom Score (TSS) at Week 24.

Quantifiable outcome

• ≥35% spleen volume reduction (SVR) from baseline at Week 24 as measured by MRI or CT scans
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Swedish Orphan Biovitrum AB (Sobi)coreStrategic or Co-development PartnerSobi is the developer and commercial sponsor of pacritinib (VONJO™). The company operates the PACIFICA clinical trial portal (churchillpharma.com) and is conducting the Phase 3 trial. Contact email [email protected] is listed on the website. Sobi holds the FDA approval for VONJO™ received February 28, 2022.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Bristol-Myers Squibb: Markets fedratinib (Inrebic), a JAK2 inhibitor approved for myelofibrosis. Directly competes with pacritinib in the JAK/myleofibrosis space and is the most analogous large-pharma competitor for Sobi/Churchill.
• GSK: Markets momelotinib (Ojjaara), a JAK1/2/ACVR1 inhibitor approved for myelofibrosis, including in patients with anemia. Directly competes with pacritinib in second-line and special-population MF settings.
• Novartis: Co-markets ruxolitinib (Jakavi) with Incyte, the standard-of-care JAK1/2 inhibitor in myelofibrosis. Pacritinib is explicitly positioned for patients who cannot tolerate standard-dose ruxolitinib, making Novartis the most relevant incumbent benchmark.
• Incyte Corporation: Co-developer of ruxolitinib (Jakavi) with Novartis — the leading JAK inhibitor in myelofibrosis. Pacritinib is being studied head-to-head against Physician's Choice which includes low-dose ruxolitinib, making Incyte a direct clinical-trial comparator.
• CTI BioPharma: Original developer of pacritinib before its acquisition by Sobi. Highly comparable given direct historical ownership of the same molecule, including prior regulatory milestones and the lineage of PACIFICA's development.

Emerging players

• Geron Corporation: Developing imetelstat, a telomerase inhibitor with positive Phase 3 data in lower-risk MDS and ongoing development in myelofibrosis. Represents a non-JAK emerging therapy that could compete with pacritinib in MF.
• Disc Medicine: Clinical-stage biotech developing therapeutics targeting iron metabolism and erythropoiesis for hematologic diseases, including myelofibrosis. Represents an emerging non-JAK modality that could overlap with pacritinib's MF patient population.
• Karyopharm Therapeutics: Develops selinexor (XPO1 inhibitor) with development activity in myelofibrosis. Represents an emerging non-JAK therapeutic modality that could compete for the same MF patient pool.

Broad incumbents

• AbbVie: Major oncology/hematology incumbent with navitoclax and other agents in myelofibrosis development. Comparable as a broad incumbent pursuing MF indications and as a potential strategic acquirer of MF assets.

Others

• Swedish Orphan Biovitrum (Sobi): The parent/affiliated entity that actually owns pacritinib and operates the PACIFICA trial. Included as the corporate parent/strategic partner rather than a competitor, but most directly comparable for business-model and pipeline analysis.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Churchill Pharmaceuticals